Clinical outcomes and treatment after drug-eluting stent failure the absence of traditional risk factors for in-stent restenosis

Circulation: Cardiovascular Interventions

Volumn 5, Issue 1, 2012, Pages 12-19

  Maluenda, Gabriel ^a   Ben Dor, Itsik ^a   Gaglia, Michael A ^a   Wakabayashi, Kohei ^a   Mahmoudi, Michael ^a   Sardi, Gabriel ^a   Laynez Carnicero, Ana ^a   Torguson, Rebecca ^a   Xue, Zhenyi ^a   Margulies, Adrian D ^a   Suddath, William O ^a   Kent, Kenneth M ^a   Bernardo, Nelson L ^a   Satler, Lowell F ^a   Pichard, Augusto D ^a   Waksman, Ron ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Correlates; Drug eluting stent; Restenosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EVEROLIMUS; HEPARIN; HIRULOG; PACLITAXEL; RAPAMYCIN; ZOTAROLIMUS;

ANGIOGRAPHY; ANTICOAGULANT THERAPY; ARTICLE; BRACHYTHERAPY; CHRONIC KIDNEY FAILURE; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DRUG ELUTING STENT; FEMALE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; IN-STENT RESTENOSIS; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RADIATION DOSE; RECURRENT DISEASE; REVASCULARIZATION; RISK FACTOR; STENT THROMBOSIS; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84860876664     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.111.963215     Document Type: Article

References (29)

1. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Juni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370:937-948. (Pubitemid 47393576)
2. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB. Safety and efficacy of sirolimus-and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998-1008. (Pubitemid 46376800)
3. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003; 349:1315-1323. (Pubitemid 37186209)
4. Weisz G, Leon MB, Holmes DR Jr., Kereiakes DJ, Clark MR, Cohen BM, Ellis SG, Coleman P, Hill C, Shi C, Cutlip DE, Kuntz RE, Moses JW. Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol. 2006;47:1350-1355.
5. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004; 109:1942-1947. (Pubitemid 38544483)
6. Mercado N, Boersma E, Wijns W, Gersh BJ, Morillo CA, de Valk V, van Es GA, Grobbee DE, Serruys PW. Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era. J Am Coll Cardiol. 2001;38:645-652. (Pubitemid 32835730)
7. Turco MA, Ormiston JA, Popma JJ, Hall JJ, Mann T, Cannon LA, Webster MW, Mishkel GJ, O'Shaughnessy CD, McGarry TF, Mandinov L, Dawkins KD, Baim DS. Reduced risk of restenosis in small vessels and reduced risk of myocardial infarction in long lesions with the new thin-strut TAXUS Liberte stent: 1-year results from the TAXUS ATLAS program. JACC Cardiovasc Interv. 2008;1:699-709.
8. Costa M, Angiolillo DJ, Teirstein P, Gilmore P, Leon M, Moses J, Yakubov S, Carter A, Fischell T, Zenni M, Bass T. Sirolimus-eluting stents for treatment of complex bypass graft disease: insights from the SECURE registry. J Invasive Cardiol. 2005;17:396-398.
9. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet. 2003;362:1093-1099. (Pubitemid 37222332)
10. Groeneveld PW, Matta MA, Greenhut AP, Yang F. Drug-eluting compared with bare-metal coronary stents among elderly patients. J Am Coll Cardiol. 2008;51:2017-2024. (Pubitemid 351680528)
11. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-2351. (Pubitemid 46685903)
12. Mehilli J, Byrne RA, Tiroch K, Pinieck S, Schulz S, Kufner S, Massberg S, Laugwitz KL, Schomig A, Kastrati A. Randomized trial of paclitaxelversus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. J Am Coll Cardiol. 2010;55:2710-2716.
13. Garg S, Smith K, Torguson R, Okabe T, Slottow TL, Steinberg DH, Roy P, Xue Z, Gevorkian N, Satler LF, Kent KM, Suddath WO, Pichard AD, Waksman R. Treatment of drug-eluting stent restenosis with the same versus different drug-eluting stent. Catheter Cardiovasc Interv. 2007; 70:9-14. (Pubitemid 47039112)
14. Lee SS, Price MJ, Wong GB, Valencia R, Damani S, Sawhney N, Gollapudi RR, Schatz RA, Teirstein PS. Early-and medium-term outcomes after paclitaxel-eluting stent implantation for sirolimus-eluting stent failure. Am J Cardiol. 2006;98:1345-1348. (Pubitemid 44666642)
15. Cosgrave J, Melzi G, Corbett S, Biondi-Zoccai GG, Babic R, Airoldi F, Chieffo A, Sangiorgi GM, Montorfano M, Michev I, Carlino M, Colombo A. Repeated drug-eluting stent implantation for drug-eluting stent restenosis: the same or a different stent. Am Heart J. 2007;153:354-359. (Pubitemid 46328767)
16. Kim SW, Mintz GS, Escolar E, Ohlmann P, Pregowski J, Tyczynski P, Hassani SE, Pichard AD, Satler LF, Kent KM, Suddath WO, Waksman R, Weissman NJ. An intravascular ultrasound analysis of the mechanisms of restenosis comparing drug-eluting stents with brachytherapy. 3 Am J Cardiol. 2006;97:1292-1298.
17. Kastrati A, Schomig A, Elezi S, Schuhlen H, Dirschinger J, Hadamitzky M, Wehinger A, Hausleiter J, Walter H, Neumann FJ. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol. 1997; 30:1428-1436. (Pubitemid 27486458)
18. Sano K, Mintz GS, Carlier SG, Solinas E, Costa Jde R Jr., Qian J, Missel E, Shan S, Franklin-Bond T, Boland P, Weisz G, Moussa I, Dangas G, Mehran R, Lansky AJ, Kreps E, Collins M, Stone GW, Moses JW, Leon MB. Treatment of restenotic drug-eluting stents: an intravascular ultrasound analysis. J Invasive Cardiol. 2007;19:464-468. (Pubitemid 350071387)
19. Castagna MT, Mintz GS, Leiboff BO, Ahmed JM, Mehran R, Satler LF, Kent KM, Pichard AD, Weissman NJ. The contribution of "mechanical" problems to in-stent restenosis: An intravascular ultrasonographic analysis of 1090 consecutive in-stent restenosis lesions. Am Heart J. 2001; 142:970-974. (Pubitemid 33131804)
20. Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation. 2005;111:2257-2273. (Pubitemid 40632443)
21. Kurmasheva RT, Huang S, Houghton PJ. Predicted mechanisms of resistance to mTOR inhibitors. 3 Br J Cancer. 2006;95:955-960. (Pubitemid 44606818)
22. Hwang CW, Wu D, Edelman ER. Physiological transport forces govern drug distribution for stent-based delivery. Circulation. 2001;104: 600-605. (Pubitemid 32738132)
23. Holmes DR Jr., Teirstein P, Satler L, Sketch M, O'Malley J, Popma JJ, Kuntz RE, Fitzgerald PJ, Wang H, Caramanica E, Cohen SA; SISR Investigators. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. JAMA. 2006;295:1264-1273.
24. Stone GW, Ellis SG, O'Shaughnessy CD, Martin SL, Satler L, McGarry T, Turco MA, Kereiakes DJ, Kelley L, Popma JJ, Russell ME; TAXUS V ISR Investigators. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA. 2006;295:1253-1263.
25. Bonello L, Kaneshige K, De Labriolle A, Roy P, Lemesle G, Torguson R, Satler LF, Pichard AD, Lindsay J, Waksman R. Vascular brachytherapy for patients with drug-eluting stent restenosis. J Interv Cardiol. 2008;21: 528-534.
26. Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Bohm M, Speck U. Treatment of coronary in-stent restenosis with a paclitaxelcoated balloon catheter. N Engl J Med. 2006;355:2113-2124. (Pubitemid 44749319)
27. El-Omar MM, Dangas G, Iakovou I, Mehran R. Update on In-stent Restenosis. Curr Interv Cardiol Rep. 2001;3:296-305.
28. Chevalier B; Cristal Investigators. Late breaking clinical trials and first report investigations: Repeat treatment strategies for drug-eluting stent restenosis: one-year results from CRISTAL, a prospective randomized study comparing Re-PTCA with cypher sirolimus-eluting stent implantation. J Am Coll Cardiol. 2010;56:xii-xvii.
29. Torguson R, Sabate M, Deible R, Smith K, Chu WW, Kent KM, Pichard AD, Suddath WO, Satler LF, Waksman R. Intravascular brachytherapy versus drug-eluting stents for the treatment of patients with drug-eluting stent restenosis. Am J Cardiol. 2006;98:1340-1344. (Pubitemid 44666639)